CoVigi phase IV multicentric trial evaluating COVID-19
vaccination effectiveness, safety, and immune response
dynamics: SARS-CoV-2-specific antibody and T-cell response
focused on patients with gastrointestinal tumors

a 2023

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ et. al.

Základní údaje

Originální název

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

Autoři

OBERMANNOVÁ, Radka (203 Česká republika, garant), Iveta SELINGEROVÁ (203 Česká republika, domácí), Regina DEMLOVÁ (203 Česká republika, domácí), Dalibor VALÍK (203 Česká republika, domácí), Lenka ZDRAŽILOVÁ DUBSKÁ (203 Česká republika, domácí) a Igor KISS (203 Česká republika, domácí)

Vydání

2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/23:00131953

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.annonc.2023.04.432

UT WoS

001037960400377

Klíčová slova česky

COVID-19; Solid cancer; multicentric trial;

Klíčová slova anglicky

COVID-19; Solid cancer; multicentric trial;

Štítky

Excelence Science, MOÚ, MU

Příznaky

Mezinárodní význam

Změněno: 2. 11. 2023 14:02, Mgr. Tereza Miškechová

Anotace

V originále

Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.

Návaznosti

LM2023049, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network

Citovat

OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ a Igor KISS. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors. 2023. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2023.04.432.

@proceedings{2327137,
   author = {Obermannová, Radka and Selingerová, Iveta and Demlová, Regina and Valík, Dalibor and Zdražilová Dubská, Lenka and Kiss, Igor},
   doi = {http://dx.doi.org/10.1016/j.annonc.2023.04.432},
   keywords = {COVID-19; Solid cancer; multicentric trial;},
   language = {eng},
   title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors},
   url = {https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub},
   year = {2023}
}

TY  - CONF
ID  - 2327137
AU  - Obermannová, Radka - Selingerová, Iveta - Demlová, Regina - Valík, Dalibor - Zdražilová Dubská, Lenka - Kiss, Igor
PY  - 2023
TI  - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
KW  - COVID-19
KW  - Solid cancer
KW  - multicentric trial;
UR  - https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub
N2  - Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.
ER  -

OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ a Igor KISS. \textit{CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors}. 2023. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2023.04.432.

Podrobný výpis o publikaci